Switch theme
Sign up to access all valuation multiples
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
2020
8
LTM Revenue $4.5M
Last FY EBITDA -$17.2M
$52.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Coya Therapeutics has a last 12-month revenue (LTM) of $4.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Coya Therapeutics achieved revenue of $3.6M and an EBITDA of -$17.2M.
Coya Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Coya Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.5M | XXX | $3.6M | XXX | XXX | XXX |
| Gross Profit | -$8.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | -186% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$17.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -485% | XXX | XXX | XXX |
| EBIT | -$21.0M | XXX | -$17.2M | XXX | XXX | XXX |
| EBIT Margin | -466% | XXX | -485% | XXX | XXX | XXX |
| Net Profit | -$19.3M | XXX | -$14.9M | XXX | XXX | XXX |
| Net Margin | -429% | XXX | -419% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Coya Therapeutics's stock price is $5.
Coya Therapeutics has current market cap of $88.1M, and EV of $52.6M.
See Coya Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52.6M | $88.1M | XXX | XXX | XXX | XXX | $-1.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Coya Therapeutics has market cap of $88.1M and EV of $52.6M.
Coya Therapeutics's trades at 14.8x EV/Revenue multiple, and -3.1x EV/EBITDA.
Equity research analysts estimate Coya Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Coya Therapeutics has a P/E ratio of -4.6x.
See valuation multiples for Coya Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $88.1M | XXX | $88.1M | XXX | XXX | XXX |
| EV (current) | $52.6M | XXX | $52.6M | XXX | XXX | XXX |
| EV/Revenue | 11.7x | XXX | 14.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.1x | XXX | XXX | XXX |
| EV/EBIT | -2.5x | XXX | -3.0x | XXX | XXX | XXX |
| EV/Gross Profit | -6.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.6x | XXX | -5.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCoya Therapeutics's last 12 month revenue growth is -20%
Coya Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $2.6M for the same period.
Coya Therapeutics's rule of 40 is -151% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Coya Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Coya Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -20% | XXX | -63% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -485% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -151% | XXX | -504% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 335% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 585% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Coya Therapeutics acquired XXX companies to date.
Last acquisition by Coya Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Coya Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Coya Therapeutics founded? | Coya Therapeutics was founded in 2020. |
| Where is Coya Therapeutics headquartered? | Coya Therapeutics is headquartered in United States of America. |
| How many employees does Coya Therapeutics have? | As of today, Coya Therapeutics has 8 employees. |
| Who is the CEO of Coya Therapeutics? | Coya Therapeutics's CEO is Dr. Arun Swaminathan, PhD. |
| Is Coya Therapeutics publicy listed? | Yes, Coya Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Coya Therapeutics? | Coya Therapeutics trades under COYA ticker. |
| When did Coya Therapeutics go public? | Coya Therapeutics went public in 2022. |
| Who are competitors of Coya Therapeutics? | Similar companies to Coya Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Coya Therapeutics? | Coya Therapeutics's current market cap is $88.1M |
| What is the current revenue of Coya Therapeutics? | Coya Therapeutics's last 12 months revenue is $4.5M. |
| What is the current revenue growth of Coya Therapeutics? | Coya Therapeutics revenue growth (NTM/LTM) is -20%. |
| What is the current EV/Revenue multiple of Coya Therapeutics? | Current revenue multiple of Coya Therapeutics is 11.7x. |
| Is Coya Therapeutics profitable? | Yes, Coya Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
